Company Profile

Amyris, Inc. is a synthetic biotechnology company. The component of the Company is derived from marketing and selling Clean Beauty, Personal Care, and Health & Wellness consumer products through its direct-to-consumer e-commerce platforms and a growing network of retail partners. The Companyâs sustainable ingredients are sold in bulk to industrial leaders who serve Flavor & Fragrance (F&F), Nutrition, Food & Beverage, and Clean Beauty & Personal Care end markets. The ingredients and consumer products it produces by its Lab-to-Market technology platform. The Company leverages machine learning, robotics, and artificial intelligence, which enables its technology platform to rapidly bring new market at commercial scale. The Lab-to-Market technology platform utilizes optimized and automated molecular biology, analytical, and process development tools combined with machine learning algorithms and statistical models to transform the way microbes metabolize sugars.

Employees

1,598

Sector

Specialty Chemicals

More about the company

Sep. 02	Amyris, Inc. Appoints Dr. Sunil Chandran as Chief Technology Officer	CI
May. 28	Amyris, Inc. acquired remaining 31% stake in Industrial Precision Fermentation Plant in Barra Bonita, Brazil from Ingredion Incorporated.	CI
24-10-03	Amyris Wins Agreement from BioMaP-Consortium to Develop Critical Medicines to Support Resilient Domestic Supply Goals	CI
24-05-07	Han Kieftenbeld to leave as Chief Financial Officer of Amyris, Inc	CI
24-05-07	Kathy L. Fortmann to Join Amyris, Inc. as Member of the Board of Directors	CI
24-05-07	Amyris, Inc. Announces Chief Executive Officer Changes	CI
24-05-07	Amyris, Inc. Emerged from Bankruptcy	CI
24-03-13	North American Morning Briefing : Stock Futures -2-	DJ
24-02-06	Third Amended Joint Reorganization Plan Approved for Amyris, Inc.	CI
24-01-22	Third Amended Joint Reorganization Plan Filed by Amyris, Inc.	CI
24-01-16	Notice for Auction Cancellation Filed by Amyris, Inc.	CI
24-01-10	US corporate bankruptcies hit 13-year peak in 2023	RE
24-01-05	Foris Ventures Provides Information to the Shareholders	CI

23-05-18	Jefferies Downgrades Amyris to Hold From Buy, Adjusts Price Target to $0.65 From $3.10	MT
23-04-28	Canaccord Genuity Initiates Amyris at Buy With $1.50 Price Target	MT
23-04-26	Piper Sandler Adjusts Amyris' Price Target to $1 From $1.50, Keeps Neutral Rating	MT
22-11-10	JPMorgan Downgrades Amyris to Underweight From Neutral	MT
22-11-09	Oppenheimer Downgrades Amyris to Perform From Outperform, Removes $22 Price Target	MT

24-01-04	Dr. Reddy's announces the acquisition of MenoLabs, a leading Women's health and dietary supplements portfolio of brands	AQ
23-11-22	Ninth Circuit Provides Guidance On SEC Rule 16b-3 Short-Swing Profit Liability Exemption	AQ
23-09-01	Amyris : Management Change - Form 8-K	PU
23-08-14	Amyris : Aviso aos Acionistas	PU
23-08-09	AMYRIS ANNOUNCES OPERATIONAL AND FINANCIAL RESTRUCTURING TO ADVANCE STRATEGIC TRANSFORMATION	PR

23-10-11	Ausblick Givaudan: 9-Mte-Umsatz von 5,31 Milliarden Franken erwartet
23-07-20	Après le 1er semestre, Givaudan se diversifie et augmente ses prix
23-07-20	Givaudan: fatturato in calo
23-04-12	Prévisions Givaudan: chiffre d'affaires de 1,79 milliard de francs
23-04-12	Ausblick Givaudan: Q1-Umsatz von 1,79 Milliarden Franken erwartet

Manager	Title	Age	Since
Kathy Fortmann CEO	Chief Executive Officer	58	2024-05-06
Sunil Chandran CTO	Chief Tech/Sci/R&D Officer	-	2005-12-31
Philip Gund PRN	Corporate Officer/Principal	63	2023-08-08

Amyris, Inc. Stock

Equities

AMRS

US03236M2008

Specialty Chemicals

Latest news: Amyris, Inc.

Analysts' recommendations: Amyris, Inc.

Press Releases: Amyris, Inc.

News in other languages: Amyris, Inc.

Managers and Directors: Amyris, Inc.

Other Specialty Chemicals

Company Profile

Director	Title	Age	Since
John Doerr BRD	Director/Board Member	73	2006-04-30
Ryan Panchadsaram BRD	Director/Board Member	40	2021-08-09
J. White BRD	Director/Board Member	57	2023-08-28

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
AMYRIS, INC.	-.--%	+100.00%	-	-	745K
ECOLAB INC.	-1.30%	+0.96%	+5.44%	+69.26%	73.24B
GIVAUDAN SA	-1.79%	+1.28%	-9.99%	+3.69%	39.52B
SIKA AG	-0.22%	+2.00%	-34.05%	-38.61%	31.4B
FUJIFILM HOLDINGS CORPORATION	-1.52%	-2.74%	-1.40%	+34.12%	25.79B
NITTO DENKO CORPORATION	-1.56%	+5.76%	+60.23%	+132.05%	17.3B
EMS-CHEMIE HOLDING AG	-0.90%	+1.19%	-13.51%	-20.79%	16.23B
SOCIEDAD QUÍMICA Y MINERA DE CHILE S.A.	+2.54%	+11.71%	+43.03%	-46.78%	15.58B
ALBEMARLE CORPORATION	+0.50%	+18.48%	+11.21%	-61.08%	13.55B
POSCO FUTURE M CO., LTD.	-4.99%	+1.21%	+25.00%	-11.23%	12.82B
Average	-0.92%	+4.27%	+9.55%	+6.74%	27.27B
Weighted average by Cap.	-1.11%	+2.70%	+3.52%	+20.91%